Ali McBride, PharmD, and Paula Anastasia, RN, MN, AOCN, discuss how results from germline and somatic HRD testing help provide new options for patients with ovarian cancer. This approach has been a “game changer” in clinical outcomes for these patients.
The Impact of Germline or Somatic HRD Testing on Treatment Decisions in Ovarian Cancer
Videos — July 14, 2020
GYN Oncology Clinical Nurse Specialist
UCLA Health
Los Angeles, CA
UCLA Health
Los Angeles, CA
Clinical Coordinator
The University of Arizona Cancer Center
Tucson, AZ
The University of Arizona Cancer Center
Tucson, AZ
